Pharmacokinetics and Pharmacodynamics Study
NCT07074236
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C
Interventions
DRUG:
QLC7401 injection
DRUG:
RBD7022 injection
Sponsor
Qilu Pharmaceutical Co., Ltd.